Supernus Pharmaceuticals, Inc. (SUPN) financial statements and ratios from SEC XBRL: revenue $0.9B (TTM), net margin -5.4%, revenue growth 8.6% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $718.95M |
| Revenue (TTM) | $0.9B |
| Net Margin | -5.4% |
| Operating Margin (TTM) | -14.5% |
| Revenue Growth (YoY) | 8.6% |
| EPS Growth (YoY) | -150.7% |
| FCF Growth (YoY) | -73.1% |
| Price / Book | 2.58 |
| Price / Sales | 3.22 |
| FCF Yield | 8.3% |
| Altman Z-Score | 5.16 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
SUPN overview · SUPN earnings · SUPN KPIs · SUPN documents · SUPN ownership · SUPN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.